Pembrolizumab plus lenvatinib for all advanced endometrial cancer? Maybe not | International Journal of Gynecologic Cancer

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens
Log in via your Society

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

Authors

About

YouTube

Podcasts

Zoom Journal Club
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens
Log in via your Society

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Article metrics

Commentary

Pembrolizumab plus lenvatinib for all advanced endometrial cancer? Maybe not

Online download statistics by month:

Online download statistics by month: February 2022 to March 2024

	Abstract	Full	Pdf
Feb 2022	0	16	15
Mar 2022	0	20	11
Apr 2022	0	14	16
May 2022	0	14	13
Jun 2022	0	9	11
Jul 2022	0	8	7
Aug 2022	0	7	2
Sep 2022	0	4	2
Oct 2022	0	8	1
Nov 2022	0	4	15
Dec 2022	0	3	2
Jan 2023	0	7	2
Feb 2023	0	6	1
Mar 2023	0	10	6
Apr 2023	0	7	3
May 2023	0	9	3
Jun 2023	0	4	2
Jul 2023	0	5	2
Aug 2023	0	4	0
Sep 2023	0	2	0
Oct 2023	0	5	4
Nov 2023	0	2	1
Dec 2023	0	6	3
Jan 2024	0	2	0
Feb 2024	0	1	3
Mar 2024	0	5	1
Total	0	182	126